BIM
KALV

BlackRock Investment Management’s KalVista Pharmaceuticals KALV Stock Holding History

BlackRock Investment Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,206
Closed -$29K – 4081
2016
Q1 		$29K Buy
3,206
+160
+5% +$2.87K ﹤0.01% 3309
2015
Q4 		$154K Buy
3,046
+15
+0.5% +$785 ﹤0.01% 3250
2015
Q3 		$152K Sell
3,031
-52
-2% -$4.43K ﹤0.01% 3275
2015
Q2 		$309K Buy
+3,083
New +$306K ﹤0.01% 3222

Other funds holding KALV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Acquisition Seattle, Washington $51.8B AUM
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

BlackRock Investment Management's KALV Position: Q2 2016 in Review

BlackRock Investment Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2016, closing a stake of 3,206 shares — an estimated $29K sold.

BlackRock Investment Management first reported a position in KALV in Q2 2015 and held it in 4 quarters. The position peaked at $309K in Q2 2015. 32 funds tracked by Wall St. Rank hold KALV as of Q2 2016.

  • BlackRock Investment Management reported no remaining KalVista Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • BlackRock Investment Management sold 3,206 KalVista Pharmaceuticals shares in Q2 2016, an estimated $29K.
  • BlackRock Investment Management first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 4 quarters.
  • BlackRock Investment Management's KalVista Pharmaceuticals position peaked at $309K in Q2 2015.
  • 32 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.